Advertisement

Improvements in the Prevention and Management of Infectious Complications After Hematopoietic Stem Cell Transplantation

  • Juan C. Gea-Banacloche
  • James C. Wade
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 144)

Introduction

Infections continue to play an important role in the management of transplant recipients and remain the primary cause of post-transplant, nonrelapse morta-lity. Several advances in the diagnosis and treatment of infections have taken place over the last few decades. It is still too early to be certain how these new approaches will impact the outcome for patients undergoing hematopoietic stem cell transplantation (HSCT), but there is no question they have impacted clinical practice. Antibiotic prophylaxis during neutropenia, new antifungal and antiviral agents, serological tests for aspergillosis and other fungal infections, the development of molecular techniques for the diagnosis of viral and parasitic infections, and the continued emergence of new pathogens are topics that are relevant and will be reviewed in this chapter.

Advances in Prevention and Treatment of Bacterial Infections After Transplantation

Prevention of Bacterial Infections

Antibacterial Prophylaxis During...

Keywords

Respiratory Syncytial Virus Hematopoietic Stem Cell Transplantation Bloodstream Infection Invasive Aspergillosis Invasive Fungal Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142(12 Pt 1):979–95.Google Scholar
  2. 2.
    van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41:1372–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–87.PubMedCrossRefGoogle Scholar
  4. 4.
    Freifeld AG, Segal BH, Baden LR, et al. Prevention and treatment of cancer-related infections. Presented at 12th Annual NCCN Conference, Hollywood. 2007. http://www.nccn.org Accessed March 2007.
  5. 5.
    Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med. 2005;353:1052–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107:1743–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117:444–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine 2007;86:69–77.PubMedCrossRefGoogle Scholar
  9. 9.
    Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000;95:3683–6.PubMedGoogle Scholar
  10. 10.
    Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49(RR-10):1–125,CE1–7.Google Scholar
  11. 11.
    Ljungman P, Engelhard D, de la Camara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005;35:737–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Kumar D, Chen MH, Welsh B, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis. 2007;45:1576–82.PubMedCrossRefGoogle Scholar
  13. 13.
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57:176–89.PubMedCrossRefGoogle Scholar
  15. 15.
    Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326:1111.PubMedCrossRefGoogle Scholar
  16. 16.
    Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002;2:231–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev (Online) 2005;:CD003914.Google Scholar
  18. 18.
    Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37:382–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607.PubMedCrossRefGoogle Scholar
  20. 20.
    Russmann H, Panthel K, Bader RC, Schmitt C, Schaumann R. Evaluation of three rapid assays for detection of Clostridium difficile toxin A and toxin B in stool specimens. Eur J Clin Microbiol Infect Dis. 2007;26:115–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Mohan SS, McDermott BP, Parchuri S, Cunha BA. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med. 2006;119:356 e7–8.PubMedGoogle Scholar
  22. 22.
    Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and nonrelapse mortality. Bone Marrow Transplant. 2000;26:871–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. (Online) 2007;:CD004610.Google Scholar
  24. 24.
    Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. (Online) 2005;:CD004610.Google Scholar
  25. 25.
    Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997;92:739–50.PubMedGoogle Scholar
  26. 26.
    Gerding DN. Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Top Microbiol Immunol. 2000;250:127–39.PubMedGoogle Scholar
  27. 27.
    Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5:549–57.PubMedCrossRefGoogle Scholar
  28. 28.
    Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2:1043–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43:421–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758–64.PubMedGoogle Scholar
  32. 32.
    Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007.Google Scholar
  34. 34.
    Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13:615–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004;53:646–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007;54:567–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther. 2006;4:601–18.PubMedCrossRefGoogle Scholar
  38. 38.
    Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005;41:754–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.PubMedCrossRefGoogle Scholar
  40. 40.
    Newman KA, Reed WP, Bustamante CI, Schimpff SC, Wade JC. Venous access devices utilized in association with intensive cancer chemotherapy. Eur J Cancer Clin Oncol. 1989;25:1375–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81:1159–71.PubMedCrossRefGoogle Scholar
  42. 42.
    Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004;22:3163–71.PubMedCrossRefGoogle Scholar
  43. 43.
    Darouiche RO, Berger DH, Khardori N, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Ann Surg. 2005;242:193–200.PubMedCrossRefGoogle Scholar
  44. 44.
    Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med. 1993;119:1168–74.PubMedGoogle Scholar
  45. 45.
    O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. The Hospital Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, U.S. Pediatrics 2002;110:e51.PubMedCrossRefGoogle Scholar
  46. 46.
    Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991;338:339–43.PubMedCrossRefGoogle Scholar
  47. 47.
    Gillies D, O’Riordan L, Carr D, Frost J, Gunning R, O’Brien I. Gauze and tape and transparent polyurethane dressings for central venous catheters. Cochrane Database Syst Rev (Online). 2003;:CD003827.Google Scholar
  48. 48.
    Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis. 2006;43:474–84.PubMedCrossRefGoogle Scholar
  49. 49.
    Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis. 1996;23:40–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect. Dis. 2007;7:645–57.PubMedCrossRefGoogle Scholar
  52. 52.
    Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med. 2005;142:451–66.PubMedGoogle Scholar
  53. 53.
    Siegman-Igra Y, Anglim AM, Shapiro DE, Adal KA, Strain BA, Farr BM. Diagnosis of vascular catheter-related bloodstream infection: a meta-analysis. J Clin Microbiol. 1997;35:928–36.PubMedGoogle Scholar
  54. 54.
    Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2004;140:18–25.PubMedGoogle Scholar
  55. 55.
    Hanna R, Raad II. Diagnosis of catheter-related bloodstream infection. Curr Infect Dis Rep. 2005;7:413–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249–72.PubMedCrossRefGoogle Scholar
  57. 57.
    Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531–40.PubMedCrossRefGoogle Scholar
  58. 58.
    Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation [see comments]. N Engl J Med. 1992;326:845–51.PubMedCrossRefGoogle Scholar
  59. 59.
    Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–52.PubMedCrossRefGoogle Scholar
  60. 60.
    Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055–61.PubMedGoogle Scholar
  61. 61.
    Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38:127–34.PubMedCrossRefGoogle Scholar
  62. 62.
    Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527–33.PubMedCrossRefGoogle Scholar
  63. 63.
    Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705–13.PubMedGoogle Scholar
  64. 64.
    Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol. 2005;131(1):22–8.PubMedCrossRefGoogle Scholar
  65. 65.
    van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16.PubMedCrossRefGoogle Scholar
  66. 66.
    Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.PubMedCrossRefGoogle Scholar
  67. 67.
    Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–34.PubMedCrossRefGoogle Scholar
  68. 68.
    Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–402.PubMedCrossRefGoogle Scholar
  69. 69.
    Maertens J, Deeren D, Dierickx D, Theunissen K. Preemptive antifungal therapy: still a way to go. Current opinion in infectious diseases 2006;19:551–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–50.PubMedCrossRefGoogle Scholar
  71. 71.
    Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764–71.PubMedCrossRefGoogle Scholar
  72. 72.
    Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.PubMedCrossRefGoogle Scholar
  73. 73.
    Wingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Am Soc Hematol Annu Meet Abstr. 2007;110:163.Google Scholar
  74. 74.
    Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472–82.PubMedCrossRefGoogle Scholar
  75. 75.
    Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidemia and invasive candidiasis: a phase III randomised double-blind trial. Lancet 2007;369:1519–27.PubMedCrossRefGoogle Scholar
  76. 76.
    Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883–93.PubMedCrossRefGoogle Scholar
  78. 78.
    Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–15.PubMedCrossRefGoogle Scholar
  79. 79.
    Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J. 2007;26:558–64.PubMedCrossRefGoogle Scholar
  80. 80.
    Foy PC, van Burik JA, Weisdorf DJ. Galactomannan antigen enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:440–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis. 2003;5:158–66.PubMedCrossRefGoogle Scholar
  82. 82.
    Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187:1834–43.PubMedCrossRefGoogle Scholar
  83. 83.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797–802. Epub 2004 Aug 27.PubMedCrossRefGoogle Scholar
  84. 84.
    O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006;58:1168–76.PubMedCrossRefGoogle Scholar
  85. 85.
    Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrobial agents and chemotherapy 2006;50:1570–2.PubMedCrossRefGoogle Scholar
  86. 86.
    Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–66.PubMedCrossRefGoogle Scholar
  87. 87.
    Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004;170:22–48.PubMedCrossRefGoogle Scholar
  88. 88.
    Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289–97.PubMedCrossRefGoogle Scholar
  89. 89.
    Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:552–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Redhead SA, Cushion MT, Frenkel JK, Stringer JR. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol. 2006;53:2–11.PubMedCrossRefGoogle Scholar
  91. 91.
    Torres HA, Chemaly RF, Storey R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jirovecii pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006.Google Scholar
  92. 92.
    De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jirovecii pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005;36:879–83.PubMedCrossRefGoogle Scholar
  93. 93.
    Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis. 1994;170:912–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6:35–43.PubMedCrossRefGoogle Scholar
  95. 95.
    Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53(RR-15):1–112.PubMedGoogle Scholar
  96. 96.
    Boeckh M, Erard V, Zerr D, Englund J. Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant. 2005;9 Suppl 7:48–54.PubMedCrossRefGoogle Scholar
  97. 97.
    Ljungman P. Viral infections: current diagnosis and treatment. Hematol J. 2004;5 Suppl 3:S63–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Sandherr M, Einsele H, Hebart H, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol. 2006;17:1051–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis. 2000;181:2055–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152:1172–81.PubMedCrossRefGoogle Scholar
  101. 101.
    Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol. 2004;25:603–8.PubMedCrossRefGoogle Scholar
  102. 102.
    David DS, Tegtmeier BR, O'Donnell MR, Paz IB, McCarty TM. Visceral varicella-zoster after bone marrow transplantation: report of a case series and review of the literature. Am J Gastroenterol. 1998;93:810–3.PubMedCrossRefGoogle Scholar
  103. 103.
    Rogers SY, Irving W, Harris A, Russell NH. Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant. 1995;15:805–7.PubMedGoogle Scholar
  104. 104.
    Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 2006;107:1800–5.PubMedCrossRefGoogle Scholar
  105. 105.
    Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543–58.PubMedCrossRefGoogle Scholar
  106. 106.
    Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol. 2004;65:432–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004;103:2003–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978–85.PubMedCrossRefGoogle Scholar
  109. 109.
    Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999;94:4029–35.PubMedGoogle Scholar
  110. 110.
    Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997;64:108–13.PubMedCrossRefGoogle Scholar
  111. 111.
    Ljungman P, Reusser P, de la Camara R, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant. 2004;33:1075–81.PubMedCrossRefGoogle Scholar
  112. 112.
    Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388–92.PubMedCrossRefGoogle Scholar
  113. 113.
    Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407–14.PubMedCrossRefGoogle Scholar
  114. 114.
    Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003;102:3060–7.PubMedCrossRefGoogle Scholar
  115. 115.
    van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant. 2006;37:693–8.PubMedCrossRefGoogle Scholar
  116. 116.
    Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:3002–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79:1477–83.PubMedCrossRefGoogle Scholar
  118. 118.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.PubMedGoogle Scholar
  119. 119.
    Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996;88:4063–71.PubMedGoogle Scholar
  120. 120.
    Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37:124–7.PubMedCrossRefGoogle Scholar
  121. 121.
    Winston D, van Burik JA, Pullarkat V, et al. Prophylaxis against cytomegalovirus infections with oral maribavir in allogeneic stem cell transplant recipients: results of a randomized, double-blind, placebo-controlled trial. Blood 2006;108:179A-A.Google Scholar
  122. 122.
    Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–40.PubMedCrossRefGoogle Scholar
  123. 123.
    Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007;69:156–65.PubMedCrossRefGoogle Scholar
  124. 124.
    Cone RW, Huang ML, Corey L, Zeh J, Ashley R, Bowden R. Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. J Infect Dis. 1999;179:311–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol. 2003;13:155–71.PubMedCrossRefGoogle Scholar
  126. 126.
    Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant. 2003;9:341–52.PubMedCrossRefGoogle Scholar
  127. 127.
    Runde V, Ross S, Trenschel R, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant. 2001;28:51–7.PubMedCrossRefGoogle Scholar
  128. 128.
    Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003;102:1114–20.PubMedCrossRefGoogle Scholar
  129. 129.
    Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2003;31:481–6.PubMedCrossRefGoogle Scholar
  130. 130.
    Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis. 2007;45:958–65.PubMedCrossRefGoogle Scholar
  131. 131.
    Randhawa PS, Demetris AJ. Nephropathy due to polyomavirus type BK. N Engl J Med. 2000;342:1361–3.PubMedCrossRefGoogle Scholar
  132. 132.
    Erard V, Storer B, Corey L, et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. Clin Infect Dis. 2004;39:1861–5.PubMedCrossRefGoogle Scholar
  133. 133.
    Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood 2005;106:1130–2.PubMedCrossRefGoogle Scholar
  134. 134.
    Bruno B, Zager RA, Boeckh MJ, et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation 2004;77:1049–57.PubMedCrossRefGoogle Scholar
  135. 135.
    Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med. 2005;352:1157–8.PubMedCrossRefGoogle Scholar
  136. 136.
    Englund JA. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol Blood Marrow Transplant. 2001;7 Suppl:2S–4S.Google Scholar
  137. 137.
    Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7 Suppl:11S–5S.PubMedCrossRefGoogle Scholar
  138. 138.
    Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis. 2004;39:673–80.PubMedCrossRefGoogle Scholar
  139. 139.
    Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44:245–9.PubMedCrossRefGoogle Scholar
  140. 140.
    Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350:443–50.PubMedCrossRefGoogle Scholar
  141. 141.
    Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144:344–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Experimental Transplantation and Immunology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations